United Kingdom peptide regulation

The UK regulates peptides under the Human Medicines Regulations 2012 (SI 2012/1916) and the Medicines Act 1968. The MHRA is the standalone regulator post-Brexit. Peptide medicines require a UK Marketing Authorisation (UKMA). Compounding is governed by Section 10 of the Medicines Act 1968. The MHRA actively investigates unlicensed peptide clinics and online vendors.

Intended-use rule

Medicinal status is assessed from the product's presentation, claims, and surrounding evidence of intended use. A not-for-human-use or research-purpose disclaimer is not decisive when the wider evidence points to medicinal use.

• MHRA: marketing authorisation, borderlines, enforcement, specials, import licensing, pharmacovigilance.

• GPhC: regulates pharmacy professionals and premises in Great Britain.

• CAP (Committee of Advertising Practice) / ASA: advertising standards for non-broadcast marketing.

• Border Force: applies border controls to imported goods, alongside the medicine-licensing decisions described in MHRA import guidance.

Key instruments:

• Human Medicines Regulations 2012 (SI 2012/1916).

• Medicines Act 1968, Section 10 — pharmacy compounding exemption.

• SI 2013/1855 — FMD initial transposition.

• SI 2019/62 — FMD safety features (disapplied post-Brexit for GB and NI).

• Medicines and Medical Devices Act 2021 — post-Brexit framework.

Licensed peptide-class medicines in the UK include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza, Saxenda), insulin analogues, teriparatide (Forsteo), leuprorelin (Prostap), goserelin (Zoladex), octreotide (Sandostatin), desmopressin, salmon calcitonin, and nafarelin (Synarel). All are prescription-only medicines (POM).

Source: MHRA marketing authorisations, https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026

Clinical trials in the UK operate under a separate regime from the EU CT Regulation. The MHRA can authorise trials through the national procedure. ILAP (Innovative Licensing and Access Pathway) offers accelerated engagement for innovative peptide therapeutics.

Source: https://www.gov.uk/government/news/the-innovative-licensing-and-access-pathway-grants-innovation-passports-to-investigational-products-for-cancer-and-dementia

Section 10 of the Medicines Act 1968 exempts pharmacists from requiring a manufacturer's licence when:

• Preparing or dispensing in a registered pharmacy pursuant to a prescription;

• Under the supervision of a pharmacist;

• For an identified patient.

The exemption does not permit stockpiling or wholesale-like supply.

Specials (Regulation 167 of HMR 2012, also IR 2012/1916): An unlicensed medicinal product can be supplied if all conditions are met:

• Unsolicited order;

• Manufactured to a prescriber's specification;

• For a patient under that prescriber's direct responsibility;

• No suitable licensed alternative;

• Made or imported by a holder of a Manufacturer's "Specials" Licence (MSL).

• Import: requires a Wholesale Distribution Licence (WDA(H)) for imports from approved countries, or an MIA/MSL from non-approved countries. A Notification of Intent to Import must be submitted to MHRA for unlicensed products; 28-day assessment period.

• Personal import exemption: no formal personal-use defence exists in UK law for unapproved medicines.

• Online: Part 14 of HMR 2012 prohibits POM advertising to the public. The joint CAP/MHRA/GPhC enforcement notice (September 2025) specifically addresses advertising of prescription-only weight-management medicines (GLP-1 agonists).

• GPhC guidance (updated February 2025): registered pharmacies offering distance-selling services must verify identity, ensure two-way communication before prescribing high-risk medicines, and not rely solely on online questionnaires.

Source: https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf

MHRA Borderlines Head Lynda Scammell (April 2026): "We disregard claims that products are for 'research purposes' if it is clear that such claims are being used as an attempt to avoid medicines regulations." The MHRA looks at promotional material, claims, dosing guidance, and FAQ content — not just label wording. Enforcement against "research peptide" vendors is active.

Source: https://www.theguardian.com/society/2026/apr/04/medicines-watchdog-to-investigate-uk-peptide-clinics-over-health-claims

UK Anti-Doping (UKAD) enforces WADA rules for UK athletes.

This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.

Related atlas pages: EU and EEA comparison, cross-border supply, approved-product label index, and WADA and sport.

1. Human Medicines Regulations 2012 (SI 2012/1916). https://www.legislation.gov.uk/uksi/2012/1916/contents

2. Medicines Act 1968, Section 10. https://www.legislation.gov.uk/ukpga/1968/67/section/10

3. ILAP Guidance. https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026

4. MHRA Import Guidance. https://www.gov.uk/guidance/import-a-human-medicine

5. GPhC Distance-Selling Guidance (Feb 2025). https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf

6. GPhC Weight Management Review (Apr 2026). https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf

7. MHRA on Peptide Clinics (Apr 2026). https://www.theguardian.com/society/2026/apr/04/medicines-watchdog-to-investigate-uk-peptide-clinics-over-health-claims